← All trials
NCT05209035
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2026
- First posted
- Jan 26, 2022
- Last posted
- Jul 20, 2022
- Enrollment
- 124
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese University of Hong KongLead sponsor
- Chinese University of Hong KongOverall official - principal investigator
- Chinese University of Hong KongReponsible party - principal investigator
- The University of Hong KongOverall official - principal investigator
- Hong Kong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.